Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE5A | O76074 | 1/20 | 0.47 |
| ▸ | PNP | P00491 | 1/20 | 0.44 |
| ▸ | XDH | P47989 | 6/20 | 0.44 |
| ▸ | GDA | Q9Y2T3 | 1/20 | 0.44 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.39 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.39 |
| ▸ | GRIA3 | P42263 | 1/20 | 0.39 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | POLA1 | P09884 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9275484 | 0.77 | PNP (0.48) | PDE5APNPXDHGDAGRIA1 | |
| SCHEMBL5323947 | 0.77 | PNP (0.48) | PDE5APNPXDHGDAGRIA1 | |
| SCHEMBL29138706 | 0.76 | PNP (0.47) | PDE5APNPXDHGDAGRIA1 | |
| SCHEMBL595204 | 0.74 | PNP (0.57) | PNPXDHGDAGRIA1GRIA2 | |
| Hydrochloric Acid SCHEMBL17186227 | 0.73 | PNP (0.56) | PNPXDHGDAGRIA1GRIA2 | |
| Hydrochloric Acid SCHEMBL17186358 | 0.73 | PNP (0.56) | PNPXDHGDAGRIA1GRIA2 | |
| SCHEMBL5133747 | 0.73 | PDE5A (0.51) | PDE5APNPXDHGDAGRIA1 | |
| SCHEMBL2435286 | 0.72 | GDA (0.57) | PNPXDHGDAGRIA1GRIA2 | |
| SCHEMBL37959 | 0.72 | PNP (0.44) | PDE5APNPXDHGDAGRIA1 | |
| SCHEMBL27762591 | 0.72 | XDH (0.50) | PDE5APNPXDHGDAPOLA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 241 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2011056630-A2 | SMALL MOLECULE INHIBITORS OF HEPATITIS C VIRUS | TRUSTEES OF BOSTON UNIVERSITY (US) | 2011-05-12 | — | — | WO | claimed |
| EP-4735462-A1 | COMPOUNDS AND USES THEREFOR | GLYCOSYNNOVATIONS PTY LTD (AU) | 2026-05-06 | — | — | EP | disclosed |
| US-20250195501-A1 | CELL ENTRY-MODULATING AGENTS AND USES THEREFOR | GRIFFITH UNIVERSITY (AU) | 2025-06-19 | — | — | US | disclosed |
| US-20250144066-A1 | Prevention and Treatment of Parasitic Infections | BARANOWITZ STEVEN (US) | 2025-05-08 | — | — | US | disclosed |
| WO-2025064458-A1 | PREVENTION AND TREATMENT OF VIRAL INFECTIONS | BARANOWITZ STEVEN (US) | 2025-03-27 | — | — | WO | disclosed |
| US-12226392-B2 | Prevention and treatment of viral infections | BARANOWITZ STEVEN (US) | 2025-02-18 | — | — | US | disclosed |
| WO-2025000059-A1 | COMPOUNDS AND USES THEREFOR | Glycosynnovations Pty Ltd (AU) | 2025-01-02 | — | — | WO | disclosed |
| US-20240299337-A1 | Prevention and Treatment of Viral Infections | BARANOWITZ STEVEN (US) | 2024-09-12 | — | — | US | disclosed |
| US-12011429-B2 | Prevention and treatment of viral infections | BARANOWITZ STEVEN (US) | 2024-06-18 | — | — | US | disclosed |
| US-20240066004-A1 | Prevention and Treatment of Viral Infections | BARANOWITZ STEVEN (US) | 2024-02-29 | — | — | US | disclosed |
| US-20050158449-A1 | Method and apparatus for coating of substrates | Surmodics Coatings, LLC | 2005-07-21 | — | — | US | disclosed |
| US-20050136483-A1 | Nanodevices employing combinatorial artificial receptors | RECEPTORS LLC (US) | 2005-06-23 | — | — | US | disclosed |
| WO-2005053835-A2 | ARTIFICIAL RECEPTORS INCLUDING GRADIENTS | RECEPTORS LLC (US) | 2005-06-16 | — | — | WO | disclosed |
| WO-2005024382-A9 | NANODEVICES EMPLOYING COMBINATORIAL ARTIFICIAL RECEPTORS | RECEPTORS LLC (US) | 2005-06-09 | — | — | WO | disclosed |
| US-20050106630-A1 | Building blocks for artificial receptors | RECEPTORS LLC (US) | 2005-05-19 | — | — | US | disclosed |
| WO-2005024382-A2 | NANODEVICES EMPLOYING COMBINATORIAL ARTIFICIAL RECEPTORS | RECEPTORS LLC (US) | 2005-03-17 | — | — | WO | disclosed |
| WO-2005024433-A2 | BUILDING BLOCKS FOR ARTIFICIAL RECEPTORS | RECEPTORS LLC (US) | 2005-03-17 | — | — | WO | disclosed |
| EP-1309360-A2 | MEDICAMENT INCORPORATION MATRIX | SurModics, Inc. (US) | 2003-05-14 | — | — | EP | disclosed |
| US-20020041899-A1 | Medicament incorporation matrix | Surmodics Coatings, LLC | 2002-04-11 | — | — | US | disclosed |
| WO-2002013871-A2 | MEDICAMENT INCORPORATION MATRIX | SURMODICS, INC. (US) | 2002-02-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250195501-A1 | CELL ENTRY-MODULATING AGENTS AND USES THEREFOR | ACE2, ACE, TMPRSS2 | PDE5A 2780/4885PNP 1477/4885XDH 1697/4885 |
| US-12011429-B2 | Prevention and treatment of viral infections | MAVS, HAVCR2, NEU4 | PDE5A 2629/4885PNP 106/4885XDH 140/4885 |
| US-20250144066-A1 | Prevention and Treatment of Parasitic Infections | EPX, CTSA, SERPINB1 | PDE5A 1428/4885PNP 404/4885XDH 310/4885 |
| US-20020041899-A1 | Medicament incorporation matrix | COL14A1, MATR3, ECPAS | PDE5A 4358/4885PNP 3921/4885XDH 1706/4885 |
| US-12226392-B2 | Prevention and treatment of viral infections | MAVS, HAVCR2, MTREX | PDE5A 3348/4885PNP 295/4885XDH 525/4885 |
| US-20240299337-A1 | Prevention and Treatment of Viral Infections | MAVS, HAVCR2, NEU4 | PDE5A 2629/4885PNP 106/4885XDH 140/4885 |
| US-20240066004-A1 | Prevention and Treatment of Viral Infections | MAVS, HAVCR2, NEU4 | PDE5A 2629/4885PNP 106/4885XDH 140/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.